Researchers at Adelaide University found that salcaprozate sodium (SNAC), used in oral semaglutide formulations, was associated with gut bacteria changes, elevated inflammatory markers, and reduced brain-derived protein levels in a 21-day animal study.
A University of South Australia study finds salcaprozate sodium (SNAC), the compound enabling oral semaglutide tablets to work, may alter gut bacteria and increase inflammatory markers in rats, though human effects remain unclear.
Alvotech announced successful clinical trial results for AVT80, a biosimilar to Takeda's Entyvio, meeting all primary endpoints. The company targets a $6.4 billion market opportunity with regulatory submissions planned.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT04528355 |
Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC |
RECRUITING | |
| NCT01962415 |
Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT |
RECRUITING | PHASE2 |
| NCT01431326 |
Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care |
COMPLETED |
